A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide (EZ) and talazoparib (TALA) for the treatment of metastatic hormone-naive prostate cancer (mHNPC): ZZFIRST.
Por:
Mateo J, Borque A, Castellano D, Castro E, Duran M, Font A, Lorente D, Mellado B, Rodriguez-Vida A, Cuadras M, Planas J, Salas I, Cordoba S, Gonzalez L, de Falcon M, Fernandez M, Sampayo-Cordero M, Malfettone A, Perez-Lopez R, Carles J
Publicada:
20 feb 2022
Resumen:
|